Anthos Therapeutics Acquisition, Valuation, Funding & Investors

Anthos Therapeutics was acquired by Novartis for $3.1B in February 2025.

Anthos Therapeutics acquisition price

$3.1B

Acquired by Novartis · Feb 2025

Cumulative funding Anthos Therapeutics raised

$250M

across 2 funding rounds

Key investors in Anthos Therapeutics

Anthos Therapeutics Overview

About Anthos Therapeutics

Anthos Therapeutics is a Cambridge-headquartered biopharmaceutical company focused on antithrombotic therapies for cardiovascular diseases. Founded in 2020, it develops abelacimab, a monoclonal antibody inhibiting Factor XI, currently in phase 2 trials for stroke prevention in atrial fibrillation patients. The pipeline also includes oral Factor XIa inhibitors, with collaborations involving Bristol Myers Squibb for early discovery programs.


Founded

2018

HQ

United StatesUnited States

Status

Acquired

Customer focus

B2B

Revenue model

Licensing

Valuation

$3.1B (acquired Feb 2025)

Anthos Therapeutics Acquisition

Anthos Therapeutics was acquired by Novartis for $3.1B on 10 February 2025.

Before the acquisition Anthos Therapeutics had raised $250M across 2 funding rounds.

Anthos Therapeutics acquisition details
AcquirerDateTypePrice
10 Feb 2025Strategic M&A$3.1B

Anthos Therapeutics Funding History

Anthos Therapeutics has raised a total of $250M across 2 funding rounds.

Anthos Therapeutics' first fundraising round was a $250M Series A in February 2019. The most recent completed round was a Series B in December 2022.

Anthos Therapeutics funding rounds

Anthos Therapeutics funding rounds
DateStageInvestorsRaisedDeal Summary
Dec 2022Series BSchroders Capital-Schroders Capital committed $2.8 million to Anthos Therapeutics through a Series B financing in December 2022, of which $0.7 million (£0.6 million) was drawn during that year, investing for Schroder UK Public Private Trust. The commitment was one of six new private investments the manager made for the trust in 2022 and sat within its life sciences bucket alongside Araris Biotech, iOnctura and A2 Biotherapeutics. Anthos Therapeutics was launched in 2019 by Blackstone Life Sciences together with Novartis, which contributed the asset that became the company's lead programme, and is based in Cambridge, Massachusetts. Its principal candidate, abelacimab, is a monoclonal antibody directed at Factor XI, designed to reduce thrombosis risk in patients with atrial fibrillation while causing less bleeding than conventional anticoagulants. The holding was realised in 2025 when Novartis agreed to acquire Anthos for $925 million upfront and up to $3.1 billion including milestones.
Feb 2019Series ABlackstone; Novartis; Novo Seeds$250MAnthos Therapeutics was launched in February 2019 as a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for high-risk cardiovascular patients, particularly through Novartis' licensed MAA868 (later abelacimab), an anti-Factor XI/XIa monoclonal antibody aimed at preventing thrombotic diseases with minimal bleeding risk. Blackstone Life Sciences provided $250 million in financing to form the company, taking control of product development, while Novartis retained a minority equity interest and licensed the key asset. The company was headquartered in Cambridge, Massachusetts, with a leadership team including CEO Martin Glasspool and board members from Blackstone. This Series A-equivalent launch round aligned with Blackstone Life Sciences' strategy of acquiring promising assets from pharma companies like Novartis and building businesses around them with capital and operational expertise. Anthos positioned itself to advance abelacimab into clinical trials for unmet needs in anticoagulation, differentiating from conventional therapies by targeting the intrinsic coagulation pathway. The company progressed abelacimab to Phase 3 trials over subsequent years. In February 2025, Novartis agreed to acquire Anthos for $925 million upfront plus up to $2.15 billion in milestones (total up to $3.1 billion), regaining the asset it had licensed out, with closure expected in H1 2025.

Who has invested in Anthos Therapeutics?

4 investors have backed Anthos Therapeutics across its funding rounds, including Blackstone, Novartis, Schroders Capital and Novo Seeds.


Anthos Therapeutics Investors

Investors in Anthos Therapeutics by funding rounds participated
InvestorHQRoundsRoleFirst check
BlackstoneUnited StatesNew York City, NY1ParticipantFeb 2019
NovartisSwitzerlandBasel1ParticipantFeb 2019

This data is available for Pro users. Sign up to see all 4 Anthos Therapeutics investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Anthos Therapeutics Competitors

Anthos Therapeutics competitors include listed companies like Tasly, Livzon Pharmaceutical Group, Jilin Aodong and Walvax Biotechnology, and private ones like NewLimit and Heyuan Biotechnology.

Public and private companies comparable to Anthos Therapeutics
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
NewLimitUnited StatesSan Francisco, CAPrivate--$3.1B-
TaslyChinaChinaPublicly listed$1.2B$265M$3.1B2.1x
Livzon Pharmaceutical GroupChinaChinaPublicly listed$1.8B$477M$3.1B1.6x
Jilin AodongChinaChinaPublicly listed$348M-$3.1B6.2x
Walvax BiotechnologyChinaChinaPublicly listed$361M$73M$3.1B10.8x
Heyuan BiotechnologyChinaShanghaiPrivate--$3B-

Anthos Therapeutics Public Comps

Anthos Therapeutics is no longer listed, but its public comps include Tasly, Livzon Pharmaceutical Group, Jilin Aodong, Walvax Biotechnology, MBX Biosciences, Celldex Therapeutics, Hebei Changshan, uniQure, Amoytop Biotech and Neuland Laboratories.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Tasly$1.2B$265M2.2x2.1x10.2x9.2x
Livzon Pharmaceutical Group$1.8B$477M1.5x1.6x5.5x5.5x
Jilin Aodong$348M-8.7x6.2x-9.2x
Walvax Biotechnology$361M$73M9.0x10.8x44.5x36.9x
MBX Biosciences-($98M)--(27.2x)(18.5x)
Celldex Therapeutics$2M($255M)1520.5x1421.3x(9.2x)(7.6x)
Hebei Changshan$130M($28M)27.0x-(123.7x)-
uniQure$16M($134M)143.6x112.7x(17.3x)(11.8x)

This data is available for Pro users. Sign up to see all Anthos Therapeutics competitors and their valuation data.

Start Free Trial

Common questions about Anthos Therapeutics

When was Anthos Therapeutics founded?Anthos Therapeutics was founded in 2018.
Where is Anthos Therapeutics headquartered?Anthos Therapeutics is headquartered in United States.
Is Anthos Therapeutics publicly listed?No, Anthos Therapeutics was acquired by Novartis in February 2025.
Who acquired Anthos Therapeutics?Anthos Therapeutics was acquired by Novartis in February 2025.
How much was Anthos Therapeutics acquired for?Anthos Therapeutics was acquired for $3.1B in February 2025.
How much funding has Anthos Therapeutics raised?Anthos Therapeutics has raised $250M across 2 funding rounds.
What was Anthos Therapeutics' last funding round?Anthos Therapeutics' last funding round was a Series B in December 2022.
Who are Anthos Therapeutics' investors?Anthos Therapeutics' investors include Blackstone, Novartis, Novo Seeds and Schroders Capital.
Which companies are comparable to Anthos Therapeutics?Companies comparable to Anthos Therapeutics include NewLimit, Tasly, Livzon Pharmaceutical Group, Jilin Aodong, Walvax Biotechnology and Heyuan Biotechnology.

See companies similar to Anthos Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial